cfDNA Fragmentome, Protein Analyses Detect Ovarian Cancer
By Elana Gotkine HealthDay Reporter
FRIDAY, Oct. 4, 2024 -- Integrated cell-free DNA (cfDNA) fragmentome and protein analyses detect ovarian cancers with high performance, according to a study published online Sept. 30 in Cancer Discovery.
Jamie E. Medina, Ph.D., from the Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins University School of Medicine in Baltimore, and colleagues used whole-genome cfDNA fragmentome and protein biomarker (CA-125 and HE4) analyses to assess 591 women with ovarian cancer, with benign adnexal masses, or without ovarian lesions.
The researchers detected ovarian cancer with specificity >99 percent and sensitivity of 72, 69, 87, and 100 percent for stages I to IV using a machine learning model with the combined features. CA-125 alone detected 34, 62, 63, and 100 percent of ovarian cancers for stage I to IV at the same specificity. Benign masses were differentiated from ovarian cancers with high accuracy (area under the receiver operating characteristic curve, 0.88). Validation of these results was performed in an independent population.
"The use of both cfDNA and protein measurements may initially appear to be complex, but both types of analytes can be assessed from the same sample of blood, and optimized methods suggest that this combined approach would be cost-efficient and accessible," the authors write. "Overall, this study provides a new accessible approach for early detection of ovarian cancer that may overcome current challenges for ovarian cancer screening and reduce the morbidity and mortality of this disease."
Several authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
Random Forest AI Model Superior for Inpatient Mortality Prognostication in Cirrhosis
THURSDAY, July 24, 2025 -- For inpatients with cirrhosis, a machine learning (ML) model using random forest (RF) analysis is superior for prediction of inpatient mortality...
Inflammation and Nutrition-Based Scores Tied to Prognosis of Low-Risk Myelodysplastic Syndrome
THURSDAY, July 24, 2025 -- The Prognostic Nutritional Index (PNI) and systemic oxidative stress (SOS) score are independently associated with poorer prognosis of low-risk...
Few School Principals Report District-Mandated Mental Health Screening
THURSDAY, July 24, 2025 -- Few school principals report district-mandated mental health screening in schools, according to a study published online July 18 in JAMA Network...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.